Quantcast

Industry news that matters to you.  Learn more

Menarini-Silicon Biosystems to Acquire CELLSEARCH CTC System

Menarini-Silicon Biosystems today announced they have signed an agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) system from Janssen Diagnostics, LLC. CELLSEARCH® is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only FDA-cleared CTC test, and has also been approved by China’s FDA for use in monitoring breast cancer patients. Financial details were not disclosed.

Veridex and LabCorp Agreement Brings CellSearch CTC Test to China

Veridex, LLC recently announced an agreement with LabCorp Clinical Trials that makes the CELLSEARCH® circulating tumor cell (CTC) test available for researchers conducting clinical trials in China. This marks the first clinical reference laboratory in China that offers CTC testing and comes on the heels of China’s State Food & Drug Administration approval of CELLSEARCH® as an in vitro diagnostic to manage patients with metastatic breast cancer.

Circulating Tumor Cells Can Provide ‘Real-time’ Information on Patient’s Current Disease State

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.